

# **Shared Health Research Application: Guidelines for Completion**

#### **GENERAL INFORMATION**

- Applications must be received at least 10 business days prior to the committee meeting, by 9 AM on the submission day. Meeting dates and submission deadlines are posted online.
- The project must be described on the Shared Health Application in a way that is consistent with how it was portrayed on the Research Ethics Board (REB) application
- For an application to be considered complete, all questions must be filled out and answers must be factually complete and contextually appropriate. Referencing the protocol or other documents, copying and pasting sections from the protocol or other documents, answering partially or in a way that is not contextually sound will not be considered an adequate answer.
- Incomplete applications will not be forwarded to the committee for review. If an application is incomplete, you will receive a response identifying the sections of the application that need to be adjusted.
- Use lay terms and avoid medical jargon and acronyms so that all reviewers have a clear understanding of the content.
- Some drop-down menus on the form allow for text to be entered if the item applicable to the project is not listed.

#### WHAT IS INCLUDED IN THIS DOCUMENT

- Guidelines for completion of (1) Shared Health Research Application
- Guidelines for completion of (2) Shared Health Research Application Amendment Form and (3) Change in Personnel Form
  - See these guidelines for general instructions and then refer back to the main application guidelines for instructions on how to fill out individual sections

For information on required documents for inclusion in submission, see the Shared Health Research and Innovation website or email SHResearch@sharedhealthmb.ca

Version Date: June 2023



## **Shared Health Research Application**

## **New Submission**

This application form is to be used for pro	ojects which have not bee	n submitted previously to Shared Health, HSC, L	Diagnostic Services or WRHA.
Date 1-Jan-23		osals for a program of research usually describe imited project. Individual projects within the Pro	
Is this project part of a Program of Research?	Yes board if (1) the and; (2) there a	owever, these will not necessarily require separa individual projects are well described in the orig re no changes to the protocol originally approve oproved 'in-principle' only	ginal ethics approval for the Program,
Specify the status of the University of Manitoba Research Ethics Board (REB) submission?	<ul><li>Submitted</li><li>Approved</li><li>Not Submitted</li></ul>	<ul><li>Health Re</li><li>Other</li></ul>	cal Research Ethics Board (BREB) esearch Ethics Board (HREB)
Total study duration Anticipated Start Da	Ethics Number te Project start date	If already known  Anticipated End Date	Project end date
D ( 1994)			

#### Protocol Title

This title must correspond to the project name on study documents such as the consent form, and has to be consistent with the title used with other regulatory bodies such as the REB (i.e. project has to go by one name).

Protocol Number	<b>Version Number</b>	<b>Version Date</b>
Most studies typically don't have a protocol number (with the		
exception of clinical trials). However, version and date should be		
provided. This allows for tracking future updated/amended versions	e.g. V1.2	e.g. 15-Apr-22
of protocol.		

#### **Protocol Objective**

Provide a clear statement of the purpose and objectives of the study

The "WHAT" question: Provide a brief statement about the project written in lay language. Explain WHAT the project is setting out to do, what it is trying to accomplish. Describe its purpose and list its specific research questions, objectives, and hypotheses that will be tested. This section may also include the context/background and rationale for the project

If this application is for a program of research, list and describe the planned research projects within the program

#### **Protocol Design**

Provide a step-by-step summary of the design and procedures of the research. Include details of any specific manipulations, interventions, measures, drug names/therapeutic classifications, etc.

The "HOW" question: Explain HOW the research project is designed and organized to accomplish its goals and answer its research questions. Focus in particular on the proposed methodology, interventions, how data will be collected, etc. If participants are involved, describe their involvement in a step-by-step manner

#### Sample Size

What is the estimated sample size for the entire study? The total number of participants/cases included in the study that are the subject of data collection and analysis (e.g. number of participants enrolled, charts reviewed). If the project is part of a multi-center initiative, specify the projected number of participants/cases for all sites

Justify the sample size on scientific grounds. If a formal sample size calculation was not used, give a rationale for the proposed number of participants.

Explain the rationale for the proposed sample size based on statistical considerations (e.g. how was it determined that the sample size is statistically sufficient).

V2 2 Page 1 of 19

#### **Data Analysis**

Primary Analysis - Outline how the data from the study will be analyzed.

How will the obtained data be analyzed in order to answer the research questions proposed by the study?ls secondary analysis of study data anticipated? (Note: secondary analysis requires further approval.)

No

Outline what plans there are for future use of the data. Is it anticipated that the research data will be used for other purposes in the future (e.g. for other projects)

Risk

Considering the level of risk this research involves and the vulnerability of the study population, make selections below that represent those levels of risk.

Participant Vulnerability	CLow	Research Risk	Clow
	<ul><li>Medium</li></ul>		<ul><li>Medium</li></ul>
	○ High		○ High

Consider the level of risk the research involves and the vulnerability of the study population.

Participant vulnerability refers to a diminished ability to fully safeguard one's own interests in the context of a specific project (TCPS 2, 2018).

Research risk should factor in the type of potential harm that might results (e.g. psychological or informational), the magnitude or seriousness of the harm (e.g. transient or permanent), and the probability of occurrence of the harm (e.g. likely or remote).

A project is considered to be low risk if the probability and magnitude of possible harms implied by participation in the research is no greater than those encountered by participants in those aspects of their everyday life that relate to the research (TCPS 2, 2018).

## **Contact Details**

Principal Investigator

The lead researcher ultimately responsible for the conduct of the study. PI is responsible for members of the research team, administration of research funds, and for ensuring that research activities are carried out in accordance with applicable laws, regulations, and policies of research sponsors, affiliated organizations (e.g. university, college, hospital, etc.), and the institution(s) where research is conducted.

If PI is a student, check off this box and fill out advisor information section that appears below/on the next page

PI is a student	L
-----------------	---

Institutional Affiliation

e.g. U of M, SH, WRHA

Department Department within the affiliated institution

Phone: Professional phone number

Email: Professional email

Reliable, professional address that is actively monitored and is suitable for receiving confidential mail Address

Has this person signed the PHIA Pledge of Confidentiality within 3 years?

Yes All members of the research team and research staff need to have completed PHIA training within the past 3 years

Will this person have access to line-level data?

• Yes Line-level data is participant/individual-level data as opposed to No aggregate data which describes whole groups

Will this person be accessing or extracting Personal Health Information from the health system? (•) Yes

Will this person require access to clinical information systems for research purposes?

Is this person going to be accessing clinical Yes information systems for research purposes  $\bigcirc$  No (note that clinical and research roles may overlap)

Specify systems List all healthcare systems this person will be accessing for research purposes including those they already have access to (e.g. Accuro, ARIA, EMR)

Is this person going to be accessing/extracting any personal health information (e.g. demographics, family/ medical/medication history, diagnoses, test results, mental health conditions, etc.) from any health system databases paper or electronic based - for research purposes

Identify the data access level

Directly identifying information

Specify the highest, most revealing level of information which will be accessed by a particular researcher (e.g. anyone accessing healthcare information systems/databases would always have access to Directly Identifying Information):

#### **ANONYMOUS INFORMATION**

Data collected anonymously that never had identifiers associated with it (e.g. anonymous surveys). The risk of identification of individuals is low or very low.

#### ANONYMIZED INFORMATION

Data that is irrevocably stripped of direct identifiers. There is no code that would allow future re-linkage to participants/cases and the risk of re-identification is low or very low.

#### **CODED INFORMATION**

Data that is stripped of direct identifiers and each participant/case is labeled with a unique code. Re-linkage is possible if necessary with the use of a "master list" retained by the principal investigator. This list links the codes with the true identity of the participants/cases.

#### INDIRECTLY IDENTIFYING INFORMATION

Data that can be reasonably expected to identify an individual/case through a combination of indirect identifiers (e.g. the combination of date of birth, place of residence, unique personal characteristics).

#### **DIRECTLY IDENTIFYING INFORMATION**

Data that identifies a specific individual through direct identifiers (e.g. name, social insurance number, personal health number).

Describe the access details

For the "DESCRIBE THE ACCESS DETAILS" question, outline what kind of information will the researcher have access to (e.g. interviews, surveys, master list, participants' charts, demographics, test results, etc.).

Think about what kind of data is being accessed and collected during the course of the study and what each person will have access to.

Will this person have remote access to data?

Yes Will this person have access to data from outside the institution they are affiliated with?  $\bigcirc$  No

V2 2

Will thi	s person be obtaining consent	? • Yes	Will this person be tasked with obtaining consent from participants?
Describ	oe the duties of this person	Describe the with respect	e role the researcher in the research project, their duties and responsibilities, especially it to contact with participants, data access, collection, extraction, analysis, dissemination of c (e.g. obtains consent from participants, collects patient data from EMR)
Resear	ch Personnel		+
Role	Co-Investigator		Use the +/- buttons to list all members of the research team and staff directly involved in the project. The list must be consistent with the personnel currently  Name  Name  REB is required. Fill out the rest of the information according to the guidelines in PI section
Institut	ional Affiliation		Department
Phone			Email
Addres	SS		
Has thi	s person signed the PHIA Pled	ge of Confid	dentiality within 3 years? Yes  No
Will thi	s person have access to line-le	vel data?	∩Yes
	•		○ No
Will thi	s person be accessing or extra	cting Persor	onal Health Information from the health system? Yes
Will thi	s person require access to clin	ical informat	ation systems for research purposes?  Yes Specify systems  No
Will thi	s person have remote access t	o data? 🔿 ነ	
	•		No
Will thi	s person be obtaining consent		Yes
		$\bigcirc$ 1	No
Describ	oe the duties of this person		

In case of general questions, contact

Member of the research team who should be contacted in case of general questions about the project

In case of patient visit questions, contact

Member of the research team who should be contacted in case of questions related to participants, study visits, etc. This person will be listed as a contact on the Diagnostic Services research requisitions (e.g. lab requisitions) if applicable.

Results are to be forwarded to

Secure Fax Number Used for faxing confidential participant results

<b>Project Information</b>				
Type of Research (select all that apply)	Faculty Research	Post-doctoral Research	Trainee R	esearch (Intern/Resident)
	Honour's Thesis	PhD Thesis/Master's The	sis Course As	ssignment
	Clinician Based or Hea	alth System Research (non-a	icademic)	
	Other			
Indicate which of the following best descri	— bes the type of investiga	tion proposed (select all the	at apply)	
	investigation proposed", co	ontinue with selection until no	new	
Basic research options app	ear. Select the closest optio	on possible, knowing that the c		
	not capture the type of you	ur research exactly		
Experimental/Clinical Study				
◯ Observational Study				
Therapy study (without interver	ition) Prognostic s	tudy 🔀 Diagnostic stud	y Observation	onal study with drugs
Secondary data analysis	Case series	Single case repo	ort	
☐ Epidemiological Research				
Secondary research				
	el 111 111 111 111			
Primary Shared Health Site/Service Locatio	n Shared Health institu by the project (e.g. F	ution at which research is bein HSC, SBH, SOGH)	g conducted and/or th	nat is primarily affected
Additional Impacted Shared Health Site(s)/	Service Location(s) Addit	tional Shared Health Institution	ns affected by the proj	ect
		riod during which enrollment a		
Estimated screening period / recruitment p		oject may run for 4 years but o pants until the end of year 2)	nly expects to recruit a	and screen new
				If project is based out of
				SH institution and/or
No make our of a green and mountified out to our out of	to imprope Charad Hoolth	. Doweite	Tatal within CII	utilizes ANY SH services or data, list the
Number of screened participants expected	to impact Shared Healtr	n Per site	Total within SH	projected number of
				participants screened
				If project is based out of SH institution and/or
				utilizes ANY SH services
Markon and the language of the control of the contr		Design	Tarak Sila Sila Sila	or data, list the
Maximum enrolled participants expected t	o impact Shared Health	Per site	Total Within SH	projected number of
				participants enrolled/ recruited
If the above two don't apply, how many re	quests are expected to in	mpact Shared Health P	er site Total	within SH e.g. number
, , , , , , , , , , , , , , , , , , , ,	1			of cases
How will the initial list of potential participation	ants/cases by identified?	Describe in detail how the	oroject will gain acces	s to potential
	•	participants/cases to be inc	luded in the study (e.g	g. posters, existing
		records, having a member of		ho is a treating physician
		to identify eligible participa	ints, etc.)	
Will existing records be used or accessed to	o identify potential partic			
		○ No		
Describe how permission will be obtained				
If SH is not the trustee of the information, perm	ission must be obtained be	fore this application can be for	warded to the commi	ttee
Will the study involve direct access to pote	ntial study participants?	<ul><li>Yes</li></ul>		
		○ No		
How will prospective participants be screen	J	cess of determining whether p		
	criteria to be included in the study (i.e. establishing eligibility). Describe the screening process in detail and outline what the inclusion/exclusion criteria are (e.g. how will you decide which			
		nat the inclusion/exclusion cri ualify to be included in the stu		
		agnosis – adenocarcinoma in s		

V2.2 Page 5 of 19

not treated with conization)

How will prospective participants be recruited? Describe the process of participant recruitment in detail (i.e. how will eligible individuals be invited to participate in the study)

Who will contact prospective participants and how will this be done?

List the members of the research team directly involved in and responsible for participant recruitment. Explain how they will solicit participant involvement in the project from the initial contact to

Describe the consent process for participants who can give fully informed consent. Provide a step-by-step description of where and how consent will be obtained.

		f giving informed consent and how this will happen in practical terr If of those who can't give informed consent	ms
Will participants be in-patients?	Yes	in of those who can't give informed consent	
here the second because	○ No		
	<ul><li>Partially</li></ul>		
Are participants SH staff?	Yes		
	○No		
	<ul><li>Partially</li></ul>		
Are all participant visits during reg	-	Yes	
	•	No	
List the services that may occur o	on off-hours and provide rationale	If any Shared Health services are required outside of regular weekday work hours, they must be outlined here. Provide justification for this request.	
	a focus of interest, or is there intent de a high proportion of First Nation:	to stratify analyses or outcomes by First Nations populations speople?	s, •Yes •No
Describe how this study will supp  The First Nations princip  Tri-Council Policy Staten	ort respectful relationships, collabooles of OCAP®	ration, and engagement, as outlined in:	<u></u>
	lutions and data sharing agreements/re	le. For more information, follow the above links. Do you have search agreements outlining the respectful relationship and	<ul><li>Yes</li><li>No</li></ul>
Is this research study regional in s	cope? • Yes		
	○ No		
Will Metis populations be a focus study population include a high p		cify analyses or outcomes by Metis populations, or will the	<ul><li>Yes</li><li>No</li></ul>
Tri-Council Policy Staten	•	ration, and engagement, as outlined in: tis, and Inuit	
Answer "yes" in case of any direct or i	indirect focus on the Metis people. For	more information, follow the above links.	
		ments outlining the respectful relationship and partnership with th	Yes
Will Inuit populations be a focus of population include a high propor		fy analyses or outcomes by Inuit populations, or will the stud	
Describe how this study will supp	ort respectful relationships, collabo	ration, and engagement, as outlined in:	ONO
<ul> <li>Tri-Council Policy Staten</li> <li>Framework for Research</li> </ul>	nent  Chapter 9 1 Engagement with First Nation, Met	tis, and Inuit	
Answer "yes" in case of any direct or i	indirect focus on the Inuit people. For r	nore information, follow the above links.	
Do you have letters of support and do with the appropriate parties?	ata sharing agreements/research agreer	ments outlining the respectful relationship and partnership	<ul><li>Yes</li><li>No</li></ul>
What services will be required? Li  Phlebotomy / Specimen Co		OVE standard of care (either altogether or at certain timepoints	

Phlebotomy / Specimen Collection Services are required for In-Patients

V2.2

□ Outpatients

Who will be responsible for Phlebotomy / Specimen Collection	n Services? 🛛 SH Lab Staff 🔲 SH Nursing Staff 🔲 Research Nurse
	Other
□ Diagnostic Services	
□ Diagnostic Imaging	
Radiologist Reports MRI - Clinical MRI -	Specialized Nuclear Medicine/PET-CT X-Ray/Ultrasound C
Guided Biopsy Angiography Radio	graphy Data Handling Other Time Requests
Cardiology	
☐ Neurology	
□ Laboratory Services	
□ Local Testing	g 🔀 Pathology
☐ Hospital In-Patient Nursing ☐ Ambulatory Care Clinic	s / Day Care Pharmacy Health Information Services
Additional Services	
Will posters and/or recruitment material be displayed within SH? $\odot$	
	No posted within SH/WRHA facilities

## **Diagnostic Imaging**

required?

Is the procedure being done as per standard of care

Is a Radiologist / Nuclear Medicine Physician report

## Radiology Is a Radiologist/Nuclear Medicine Physician required for this study? Yes No Is there a preference for a Radiologist/Nuclear Medicine Physician? Yes No List those tests or procedures performed, which are above standard of care **Tests or Procedures** Use the drop-down menu to specify the radiology test/procedure to be performed Specific Visit(s) List the specific study visits during which the specified test/procedure is required (e.g. Screening, Week 8, Progression, End of Treatment, etc.). Only list those time points at which the required test/procedure is above standard of care Site (if not applicable to all) If different from primary site Specific conditions for requirement of procedure if not required for all If the test/procedure is not required for all participants, outline the conditions under which it is indicated for certain participants Specify body part(s) List the body part(s) targeted by the required test/procedure

○ No

Yes

No

• Yes Should the procedure be performed the way it would normally be done if

ordered clinically (i.e. as per clinical standard)

V2.2

## **Laboratory Services**

## Local Testing (excluding pathology)

List those tests or procedures performed in-house by the SH Diagnostic Services lab(s), which are above standard of care **Test Names or Procedures** Specific Visit(s) Site (if not applicable at all) List all required in-house tests performed by Shared Health labs that are above standard of care (either altogether or for specific visits). For each test, list the study visit(s)/ List the site(s) at which the testing is to be IMPORTANT: Consult the Lab Information timepoints during which the test will be performed if different from the main site Manual (LIM) and use test names as they appear ordered (e.g. Screening, Week 8, in LIM. Tests not listed in LIM are not offered by Progression, End of Treatment) Shared Health. \*EXAMPLE\* (tests grouped by study visits) Biochemistry: Sodium, Potassium, Direct Screening (baseline), Week 8, EOT (end of HSC, SBH Bilirubin, Total Bilirubin, Calcium treatment) Hematology: Prothrombin time (INR) Biochemistry: Sodium, Calcium Week 4 HSC, SBH Biochemistry (urine): Urinalysis (dipstick only)

## Central Lab Processing / Shipping (excluding pathology)

Is Shared Health Laboratory Staff responsible for sample processing and/or shipping? Processing Yes Shipping **Partially** 

Describe sample processing and/or shipping services to be done by Shared Health Laboratory Staff

If SH labs are required to process/store/ship samples that will be tested elsewhere, Lab Manual must be provided as part of submission

## **Pathology**

**Timepoints** 

Screening

Specify details of specimens required	+ -		
Disease site group Choose the anato	omical type of specimen (e.g. Gastrointestinal, Genitourinary, Head & Neck)		
Type of Tissue Normal/Tumor	Tissue Obtained Archival/Newly Obtained		
Specimen Required - Primary	Specimen Required - Primary Specify the primary (preferred) request for procedure/deliverables		
Specimen Required - Alternative	Specimen Required - Alternative Specify an alternative request in case primary request cannot be granted		
Limonointe	sits during which the procedure/deliverables are required (e.g. Screening, Week 8, Progression, End of hich they are above standard of care. (see examples below)		
Disease site group *EXAMPLE* Gent	itourinary		
Type of Tissue Tumour	Tissue Obtained Archival (retrospective)		
Specimen Required - Primary	1 FFPE tumor block		
Specimen Required - Alternative	20 unstained, unbaked, charged slides at 4 micron thickness & 1 H&E slide		

V2 2 Page 9 of 19

Disease site group *EXAMPLE* (Cor	nt) Genitourinary	7
Type of Tissue Tumour	Tissue Obtained (prospective)	_
Specimen Required - Primary	1 FFPE tumor block from each biopsy site & 1 freshly obtained tissue in formalin	
Specimen Required - Alternative	n/a	
Timepoints Recurrence / Progression		_
<u>Data Required</u>		
Pathology Data Yes	Patient Related Parameters  Yes	
<ul><li>No</li></ul>	<ul><li>No</li></ul>	
Terms of Agreement (to be completed	d by each Designated Pathologist)	

1. Research as part of non-clinical workload

Research work in lieu of clinical workload, as approved by SH Pathology Medical Director

Time Estimate (per case)

2.

The amount of time estimated by project/ collaborating pathologist for review of each case

**IMPORTANT:** It is no longer necessary to recruit SH pathologist for projects with pathology component. If no collaborating SH pathologist is recruited, pathology requests will be reviewed by an assigned index pathologist who will review tissue availability and release samples. Index pathologist will not be responsible for familiarizing themselves with any special project requirements beyond basic information on study requisition. In case of elaborate tissue selection criteria, it is still advised to recruit a SH pathologist

**Designated Pathologist** 

Name Read the fine print below for more info

Signature

Date

#### Add Additional Pathologist

The Designated Pathologist must have an appointment at the hospital site from which tissue will be obtained. The Designated Pathologist is aware of the tissue requirements outlined in the protocol and agrees to be the main pathology contact person in partnership with the Principal Investigator, and will be responsible for the selection of tissue (blocks/slides) to be released. If research work is being done in lieu of clinical workload, approval by the SH Pathology Medical Director will be required. The SH Research & Innovation will file the appropriate documentation to obtain this approval.

V2 2 Page 10 of 19

## **Health Sciences Center Services**

Specify the main areas within HSC where study activities will be carried out including office space

Specify the HSC building(s) and room(s) where the study will be conducted  $% \left( 1\right) =\left( 1\right) \left( 1\right)$ 

NOTE: Locations of services previously described in detail such as HSC phlebotomy lab or MRI department do not need to be listed here

Hospital In-Patient Nursing	
Indicate which nursing services are required:	+ -
Unit(s) Specify which nursing units will be involved specifically (use +/- to add sections if multiple nursing units involved we Below specify the activities/services that are required of them:	rith different activities).
	equent Observation ablishing of IV
Frequency Specify the frequency of every activity selected above (e.g. check blood pressure every 4 hours, administer stude every 12 hours)	y drugs
Position Research Nurse Staff Nurse Other  Participant Age Adult Pediatric  Will the study increase Nurse:Patient Ratio (1:1, 2:1, 4:1, 6:1, Other) Yes  No	
What incremental supplies are required? List the one-time use/disposable supplies that are required to carry out the required whether these will be provided by the study (e.g. intravenous cannula, catheter,	
Ambulatory Care Clinics / Day Care Indicate which units or clinics will be providing service, which are above standard of care Unit(s) or Clinic(s) For this section, refer to instructions found in the "Hospital In-Patient Nursing" section above Activity Receiving & Registering Appointment Scheduling Medical Record Management Patient Education Participant Enrollment Other  Frequency Position Clerk RN Assistant Other	Assessment
Health Information Services  Will information from individual patient charts or medical records be required?    ○ Yes  ○ No	
Describe Outline in detail what kind of information will be collect	ed from each chart
Explain how patient charts or medical records to be extracted will be identified  How will the HIS know which charts to you instruct them regarding what where the properties of the properties	select. How will It you need.
Will a list of required charts or medical records be provided to the organization maintaining the records for extract	
Approximately how many charts or medical records will be required? e.g. 100	0110
Who will be the person/people responsible for accessing and extracting the patient charts or medical records?	Which member(s) of the research team will extract the information from the records once they are made available by HIS
Will Health Information Services be required to produce a list of chart numbers (based on criteria that you provide)	•
Comments/Other information relevant to chart review	<b>©</b> 110

V2.2 Page 11 of 19

## **WRHA Facilities & Resources**

Are any WRHA or affiliated facility resources required including employee partic	cipation, space, equipment, or money:   Yes
	○ No
Specify and indicate how much, how many and for what period of time:	
Outline in detail the requirements for facility resources, staff involvement, the use of spinterviewed outside of their shift)	ace, equipment, or WRHA funding (e.g. HSC ER nurses will be
It is incumbent upon the researcher to negotiate the dedication of WRHA resou	urces to this project prior to submission. Please include a
written statement of support from the Managers directly in control of all the re-	sources required. In cases where a manager is also a co-
investigator, the level of support must come from at least one level above that	individual.
Is there written support from the program area? 🌘 Yes	
○ No	
Will the study involve correspondence with potential participants that is mailed	d out? Yes
	<ul><li>No</li></ul>
Will information from individual patient charts or medical records be required?	○ Yes
	<ul><li>No</li></ul>
Explain how patient charts or medical records to be extracted will be identified.	If patient records from WRHA institutions are required (other than those obtained from HSC Health Information Services), specify how the charts/records will be identified
Will a list of required charts or medical records be provided to the organization	maintaining the records for extraction?        Yes
	○ No
Approximately how many charts or medical records will be required? e.g. 10	00
Who will be the person/people responsible for accessing and extracting the pa	tient charts or medical records?
Will Health Information Services be required to produce a list of chart numbers	(based on criteria that you provide)? Yes
	<ul><li>No</li></ul>

V2.2 Page 12 of 19

## **Data Access and Disclosure Plan**

Shared Health and WRHA Data Access and Disclosure Plan (RAAC Spec Sheet for Populating Data Sharing Researcher Agreements)

Date 1-Jan-23	This section is pre-populated by information entered in the "Contact Details" section
Principal Investigator	The lead researcher ultimately responsible for the conduct of the study. PI is responsible PI is a student
nstitutional Affiliation	e.g. U of M, SH, WRHA  Department Department within the affiliated institution
Phone	Email Professional phone number & email
Address Reliable, pro	fessional address that is actively monitored and is suitable for receiving confidential mail
Data Elements, Disclosu	
<ol> <li>Specify the total dat</li> </ol>	te range for the data required e.g. Jan 2000 to e.g. Dec 2025
Specify the date range	e of the required Shared Health/WRHA data that will be accessed and/or extracted for research purposes. The date range can
be purely retrospectiv	ve or end in the future if SH/WRHA data collected during the lifetime of the project is going to be reviewed (e.g. research tear
wants to review retros	spective data collected between Jan 2000 and now. They also wish to continue looking at prospective patient data in Accurd
that will be collected i	in the future during the lifetime of the project, and they will do so until the end of the project in Dec 2025. The date range
correct date range for	them is Jan 2000 - Dec 2025).
Specify the Inclusion	n/Exclusion criteria related to data elements
Outline which charact	teristics expressed as data elements will serve as inclusion/exclusion criteria determining eligibility as SH/WRHA data is
reviewed (e.g. INCLUS	SION CRITERIA: gender – female, age - ≥18, diagnosis – adenocarcinoma in situ, EXCLUSION CRITERIA: surgical history – not
treated with conizatio	on)
Is a control group re	equired to be extracted for this study?
	No
	C

Describe the matching ratio and criteria for the control group and provide a rationale for the specific parameters requested If the project requires that a control group is created using SH/WRHA data, outline the required characteristics and justification

- 2. Complete the Data Extraction Form which summarizes all the data fields expected to be received and/or accessed
- 3. Complete the Data Flow Table which summarizes how the data will be sent from one institution to another
- 4. Complete the Data Security Table which summarizes how data security will be maintained

## **Data Details Form**

Name of Database / System Requested	Data Trustee (Shared Health, WRHA, etc.)	Service Provider (HIS, Self-discolsure, etc.)	Data Fields / Variables	Date Range of Data Requested	Rationale
List all health databases/systems accessed for research ousposes, including those that the research team already has access to as part of their clinical or research capacity. List system individually and be specific (e.g. list Accuro instead of EMR)	List the institution that is the trustee of the data  NOTE: Individuals are not data trustees, institutions are.	The individual/ department who is directly accessing and/or extracting information from the system/database (eg. HIS, data analyst). If a member of the research team is accessing the data directly, put "self- disclosure"	Specify all accessed / extracted data items These can be listed in a separate document such as Data Collection / Extraction Sheet	Specify the date of the oldest and newest information that will be accessed/extracted from a particular database/system (The date range can be purely retrospective or can end in the future if SH/WRHA data is going to be accessed prospectively during the course of the project)	Explain why it is necessary for the research project to access each of the listed databases/ systems and to view/ extract the outlined data items

## **Data Flow**

Will data be moved from one location to another? 

• Yes



 $\bigcirc$  No

Whenever Shared Health / WRHA data is accessed from or sent to another location - either physically or electronically - this is considered data flow and must be declared here. This includes accessing Shared Health/WRHA databases outside of Shared Health/WRHA (such as from a U of M location) or extracting data onto laptop or flash drive and keeping or accessing it outside of the trustee's premises and servers

+ -

V2.2 Page 14 of 19 Complete the following data flow table and clearly indicate at what stage personal health information will be de-identified. The Personal Health Information Act requires that every disclosure by a trustee of personal health information must be limited to the minimum amount of information necessary to accomplish the purpose for which it is disclosed. Information flow number depends the level of information flow, it is not linear Information Flow Number numbering system (e.g. think of a family tree where different family members in the same generation would be on the same level). Sender Organization The trustee of the data (e.g. SH or WRHA) Receiver Organization The organization that is receiving the data from the trustee (e.g. U of M) Outline what data is being accessed/extracted/transferred and whether the data is directly identifying, de-identified, coded, etc. Describe the data being transferred \*EXAMPLE\* DIRECTLY IDENTIFYING DATA: participant's name, DOB, data indicating eligibility, medical and surgical history, medication history, pathology/lab/diagnostic imaging reports How will data be transferred from the sender organization to the receiving site (e.g. secure Method used to securely transfer data network connection) What tasks will be performed at the receiving site (e.g. extraction of information, Description of functions performed at this location coding of data, statistical data clean-up, storage of coded data and master list) Yes Will the sender keep a copy of the transferred data? ○ No ○ No Information Flow Number Sender Organization \*EXAMPLE\* (Cont) University of Manitoba Receiver Organization Study Sponsor CODED DATA STRIPPED OF DIRECT IDENTIFIERS: participant code, age, data indicating Describe the data being transferred eligibility, medical and surgical history, pathology/lab/imaging reports Method used to securely transfer data **REDCap** Description of functions performed at this location Data analysis, writing of manuscript, publication of research results Will the sender keep a copy of the transferred data? Yes  $\bigcirc$  No Does any member of the research team have access to the data at the receiving location? \( \text{Yes} \) No **Data Security** Identify the physical locations where data will be used or accessed by the research team, and storage sites (if different). Location e.g. University of Manitoba Physical location(s) where data will be accessed and/or stored Address Digital files, Onsite server How will data be stored during the study? ☐ Hard copies Personal computer CD/DVD Digital files, Offsite server Portable hard drive Laptop Other Anticipated date of destruction Will data be accessed remotely? Yes

○ No Where will Master Key be kept? e.g. Principal Investigator's office - Room 123A Buller Bldg.

What is the anticipated length of time that the research team will have access to the data? When will access to electronic system housing the data be terminated for the research team?

How long will the study data be retained after the analysis is completed (number of years)?

Start

End

Describe what will happen to the data at the end of the study and, if applicable, the procedures used to destroy study data contained in written records, videotapes, computers files and questionnaires, etc.

e.g. Physical copies will be pulverized, data saved on portable hard drive will be deleted and hard drive formatted

Identify all agencies or collaborators who will have access to the data (including medical records) at each stage of collection, processing, and analysis for the purpose of monitoring and/or auditing of data.

Any other entities with whom study data will be shared (e.g. collaborating universities, etc.)

## **Funding / Billing Information**

res, wholly
es, partially
No
<b>/</b> ∈



Fund will be administered by

e.g. University of Manitoba

Special considerations

**Primary Billing Contact** 

Name Contact for all billing inquiries whose name will appear on any relevant invoices

Phone Professional phone number Email Professional email address

Address Reliable, professional address that is actively monitored and is suitable for receiving confidential mail

#### **Other Information**

Describe any other information relevant to this application

#### **Declaration**

I hereby declare that the information provided in this application is true and correct to the best of my knowledge and belief. In case any information given in this application proves to be false or incorrect, I shall be responsible for the consequences, including but not limited to, delay in approval or rejection in full of this application.

## For projects requiring identifiable personal health information:

Where identifiable personal health information is requested, I declare that this research cannot be done without using identifiable personal health information, and that it is impossible or impractical to obtain consent from the people the personal health information is about.

The lead researcher ultimately responsible for the conduct of

## **Documents**

Provide a listing of all documents that will be included with this application. Required documentation is listed on the SH Research and Innovation website.

d	+
	-

Туре	Title/Name	Version Number and/or Date
	All applicable documents that are part of the submission must be listed in this table	



## **Shared Health Research Application**

## **Amendment**

This application form is to be used for project amendments which impact or alter the original services requested.				
Date	SH Reference Number			
Principal Investigator				
Protocol Title				
Type of Submission ⊠ Amendment ☐ Extension ☐	Alternative Site Documentation Participant/Case Increase			
Note: the basic principle of this form is to (1) select all areas/elements of outline in each section on the following pages what is different compare For definitions of the items under "Amendment Summary", please see the	ed to the initial submission and/or subsequent amendments.			
Amendment Summary				
Identify all areas that will be impacted by the proposed change.				
Protocol Information	Project/Population Information			
Study Duration	☐ Shared Health Site/Service Location			
☐ Protocol Title	☐ Number of Participants / Cases			
☐ Protocol Objective	Participant/Case Information			
☐ Protocol Design	☐ First Nations Population			
☐ Sample Size				
☐ Data Analysis	☐ Inuit Population			
Risk				
Service Information				
☐ Phlebotomy / Specimen Collection	Health Sciences Center - Location			
Diagnostic Imaging - Radiology	Health Sciences Center - Hospital In-Patient Nursing			
Diagnostic Imaging - Cardiology				
Diagnostic Imaging - Neurology				
Laboratory Services - Local Testing Health Sciences Center - Health Information Services				
Laboratory Services - Central Lab Processing / Shipping	Health Sciences Center - Additional Services			
Laboratory Services - Pathology	☐ WRHA Facilities & Resources			
Poster and/or Recruitment Material Displayed	☐ Data			
☐ Funding	☐ Documents			
Rationale Provide Rationale for proposed changes above.				
For each applicable area/element selected above, explain why the prop	osed changes are happening			
In the following sections, provide details of the proposed chan	ges. In some sections an outline of the current state is required as well.			

V2.1 Page 1 of 3

In each section, think about what is changing compared to the initial application and/or subsequent amendments. Unless requested, do not outline what remains the same. When making changes to existing services such as radiology, laboratory testing, pathology, etc, describe what needs to be removed, added, or changed in comparison to what the project is already getting.

EXAMPLE (A): In the example below, a project has been approved for MRI of brain at HSC at the time of participant screening, but now they want to request CT of the same instead. To capture this, they first describe the existing service (1) and choose "Remove" next to "Status". Next, they use the "+/-" button to add another subsection and (2) describe their request for CT.

Diagnostic Imagi	i <b>ng - Radiology</b> ear Medicine Physician required f	for this study? O Vee		
is a natiologist/Nucle	ear Medicine Physician required i	for this study? Yes  No		e "+/-" buttons add subsection
) List those tests or pro	ocedures performed, which are a	bove standard of care		+ -
Tests or Procedures	MRI-Clinical		Status	Remove
Specific Visit(s)	Screening		_	
Site (if not applicable	to all) HSC			
Specific conditions for	or requirement of procedure if no	ot required for all n/a		
Specify body part(s)	Brain			
Is the procedure bein	g done as per standard of care	• Yes		
		○ No		
•	lear Medicine Physician report	○ Yes		
required?		<ul><li>No</li></ul>		
Tests or Procedures	MRI-Clinical		Status	Add
Specific Visit(s)	End of Treatment (EOT)			
Site (if not applicable	to all) HSC			
Specific conditions fo	or requirement of procedure if no	ot required for all n/a		
Specify body part(s)	Brain			
Is the procedure bein	g done as per standard of care	• Yes		
		○ No		
-	lear Medicine Physician report	○ Yes		
required?		<ul><li>No</li></ul>		
service and adding a n	new services which is the same with	but wants to now change it to Lumbar Spine. Instead of removing the the exception of scanned body part, the research team chooses to out in the existing and new requests are sufficiently similar.		
Tests or Procedures	СТ		Status	Change
Specific Visit(s)	Screening			
Site (if not applicable	to all) HSC			
Specific conditions for	requirement of procedure if not	t required for all n/a		
Specify body part(s)	Lumbar Spine			
Is the procedure being	g done as per standard of care	Yes		
		○ No		
•	ear Medicine Physician report	○ Yes		
required?		<ul><li>No</li></ul>		

V2.1 Page 2 of 3

## **Other Information**

Describe any other information relevant to this application

#### **Declaration**

I hereby declare that the information provided in this application is true and correct to the best of my knowledge and belief. In case any information given in this application proves to be false or incorrect, I shall be responsible for the consequences, including but not limited to, delay in approval or rejection in full of this application. I understand that, if applicable, overhead charges may be applied based on current Shared Health rates.

#### For projects requiring identifiable personal health information:

Where identifiable personal health information is requested, I declare that this research cannot be done without using identifiable personal health information, and that it is impossible or impractical to obtain consent from the people the personal health information is about.

#### Completed by:

Amendment application may be signed by the PI or main study coordinator

V2.1



## **Shared Health Research Application**

## **Change in Personnel**

This application form is to be used to add, remove or alter the personnel/duties involved in a project			
Date	SH Reference Number		
Principal Investigator			
Protocol Title			
Use this form in the event of personnel changes. List all members of the research team who has changed since the initial application and/or subsequent Change in Personnel forms.	have been (1) added , (2) removed, or (3) whose information		
For detailed instructions on how to fill out individual items below, please see the correspond	ing sections of the main application.  Use "+/-" button to add additional people		
Contact Detail Changes	+ -		
Role	Status Choose (1) Add, (2) Remove, or (3) Change		
Name			
Name			
Institutional Affiliation Department			
Phone Email			
Address			
Has this person signed the PHIA Pledge of Confidentiality within 3 years? Yes			
○ No			
Will this person have access to line-level data?			
○ No			
Will this person be accessing or extracting Personal Health Information from the he	ealth system? Yes		
	○ No		
Will this person require access to clinical information systems for research purposes	s?  Yes Specify systems		
	○ No		
Will this person have remote access to data? Yes Will this person b	e obtaining consent? Yes		
○ No	○ No		
Describe the duties of this person			
In case of general questions, contact			
In case of patient visit questions, contact			
Results are to be forwarded to	Secure Fax Number		
Other Information			

## **Declaration**

I hereby declare that the information provided in this application is true and correct to the best of my knowledge and belief. In case any information given in this application proves to be false or incorrect, I shall be responsible for the consequences, including but not limited to, delay in approval or rejection in full of this application.

This application can only be signed by the PI

Describe any other information relevant to this application

V2.1 Page 1 of 1